US Bancorp DE Sells 1,380 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

US Bancorp DE lessened its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 53.3% during the 4th quarter, Holdings Channel reports. The firm owned 1,209 shares of the company’s stock after selling 1,380 shares during the period. US Bancorp DE’s holdings in CRISPR Therapeutics were worth $48,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CRSP. State of New Jersey Common Pension Fund D raised its stake in CRISPR Therapeutics by 16.8% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 40,341 shares of the company’s stock valued at $1,895,000 after purchasing an additional 5,803 shares during the period. KBC Group NV grew its holdings in CRISPR Therapeutics by 43.9% during the 3rd quarter. KBC Group NV now owns 2,818 shares of the company’s stock valued at $132,000 after buying an additional 860 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in CRISPR Therapeutics by 1.0% during the 3rd quarter. Thrivent Financial for Lutherans now owns 47,696 shares of the company’s stock valued at $2,241,000 after buying an additional 473 shares in the last quarter. Advisors Asset Management Inc. grew its holdings in CRISPR Therapeutics by 3.7% during the 3rd quarter. Advisors Asset Management Inc. now owns 9,669 shares of the company’s stock valued at $454,000 after buying an additional 342 shares in the last quarter. Finally, Darwin Wealth Management LLC purchased a new position in CRISPR Therapeutics during the 3rd quarter valued at approximately $43,000. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Down 4.3 %

Shares of CRISPR Therapeutics stock opened at $40.97 on Wednesday. The stock’s fifty day moving average is $43.04 and its two-hundred day moving average is $45.47. The company has a market capitalization of $3.51 billion, a PE ratio of -9.38 and a beta of 1.76. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $75.91.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CRSP. Chardan Capital cut their price target on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Barclays raised their price target on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Bank of America cut their price target on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Finally, Royal Bank of Canada cut their target price on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $73.11.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the company’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now directly owns 171,613 shares in the company, valued at approximately $9,473,037.60. This represents a 9.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Julianne Bruno sold 1,198 shares of the company’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the sale, the chief operating officer now owns 8,263 shares of the company’s stock, valued at $350,516.46. This represents a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,381 shares of company stock worth $1,608,243. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.